For patients with a strong family history without a known genetic mutation and patients with other breast cancer risk genes such as CHEK2, PALB2, and CDH1, there is insufficient evidence regarding CBC risk to recommend for or against CPM in these patients, and therefore CPM can be considered. The gene discussed is CHEK2; the disease is breast carcinoma.